|Bid||0.00 x 900|
|Ask||358.00 x 800|
|Day's range||350.26 - 356.46|
|52-week range||282.21 - 387.42|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||26.38|
|Earnings date||05 Feb 2024 - 09 Feb 2024|
|Forward dividend & yield||N/A (N/A)|
|1y target est||400.00|
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.
These stocks are already big winners in 2023 and should keep their momentum going in a new bull market.
Vertex Pharmaceuticals (NASDAQ: VRTX) has come a long way in the past ten years. In a little over a decade, the company has built a cystic fibrosis (CF) empire, commercializing four drugs for the disease that together generate blockbuster revenue . Now, whether you're a Vertex investor or a potential one, you may be wondering what's next for this big biotech.